<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340895</url>
  </required_header>
  <id_info>
    <org_study_id>7002661</org_study_id>
    <nct_id>NCT04340895</nct_id>
  </id_info>
  <brief_title>Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study)</brief_title>
  <acronym>OPTIMISE</acronym>
  <official_title>Pragmatic Randomized Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide evidence that a therapy of Ulcerative Colitis (UC)&#xD;
      disease adjusted on tight monitoring of non-invasive parameters, such as clinical symptoms&#xD;
      and faecal calprotectin (FC) (substance that is released when intestines are inflamed and&#xD;
      that can be measured in faeces), can provide significantly higher benefit for the&#xD;
      participants in terms of disease control and quality of life (QoL) improvement, compared to a&#xD;
      symptom-based approach only.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Mayo Endoscopic Sub-score = 0</measure>
    <time_frame>At 12 months</time_frame>
    <description>Defined as the percentage of participants achieved mucosal healing (Mayo endoscopic sub-score of 0 [normal friability]). The Mayo endoscopic scoring ranges from 0-3 with higher scores indicating greater disease severity. The score is defined as 0-3: 0= Normal; 1=Mild friability; 2 = Moderate friability; 3 = Exudation, spontaneous hemorrhage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Rectal Bleeding = 0</measure>
    <time_frame>At 12 months</time_frame>
    <description>Defined as the percentage of participants with no RB (RB=0). The RB score ranges from 0-3 with higher scores indicating greater disease severity. The score was defined as 0-3: 0 = None; 1 = Streak of blood; 2 = Obvious blood; 3 = Mostly blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Stool Frequency &lt;=1</measure>
    <time_frame>At 12 months</time_frame>
    <description>Defined as the percentage of participants with SF&lt;=1. The SF score ranges from 0-3 with higher scores indicating greater disease severity. The score was defined as 0-3: 0 = None; 1 = 1-2 stools/day &gt; normal; 2 = 3-4 stools/day &gt; normal; 3 = &gt;4 stools/day &gt; normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Mayo Endoscopic Sub-score &lt;=1</measure>
    <time_frame>At 12 months</time_frame>
    <description>Defined as the percentage of participants achieved endoscopic remission (Mayo endoscopic sub-score &lt;=1 [normal or mild friability]). The Mayo endoscopic scoring ranges from 0-3 with higher scores indicating greater disease severity. The sub-score was defined as 0-3: 0 = Normal friability; 1 = Mild friability; 2 = Moderate friability; 3 = Exudation, spontaneous hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</measure>
    <time_frame>From Baseline over 12 Months</time_frame>
    <description>Defined as a change in the QoL using SIBDQ over 12 months. The SIBDQ consists of 10 questions, measuring systemic, social, Bowel, and emotional status; each question is scored on a scale from 1 (poor QoL) to 7 (optimum QoL). A higher score indicates a better QoL. Total scores range from 10 (poor QoL) to 70 (good QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form Questionnaire-36 (SF-36)</measure>
    <time_frame>From Baseline over 12 Months</time_frame>
    <description>The SF-36 is a health-related survey that assesses participant's QoL and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental component score and physical component score). Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Escalated to Rescue Therapy</measure>
    <time_frame>Over 12 months</time_frame>
    <description>Rescue therapy included systemic corticosteroids/ immunosuppressants /biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Productivity and Activity Impairment: Ulcerative Colitis (WPAI: UC) Questionnaire</measure>
    <time_frame>From Baseline over 12 Months</time_frame>
    <description>The WPAI-UC is a questionnaire with 6 questions used to evaluate lost productivity (work time missed and work and activity impairment) during the past 7 days due to UC. The scores are presented as percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalization Days</measure>
    <time_frame>Over 12 months</time_frame>
    <description>Number of hospitalization days will be determined by UC related medical resources.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Outpatients Visits and Calls (Outside of Study Schedule)</measure>
    <time_frame>Over 12 months</time_frame>
    <description>Number of outpatients visits and calls (outside of study schedule) will be determined by UC related medical resources.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ulcerative Colitis Related Procedures and/or Surgeries</measure>
    <time_frame>Over 12 months</time_frame>
    <description>Number of UC related procedures and/or surgeries will be determined by UC related medical resources.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal Calprotectin Value Changes at the Defined Study Time Points (Interventional Arm Only)</measure>
    <time_frame>Over 12 months</time_frame>
    <description>The FC Test will be done by the participant at home every month during active disease, every 3 months in remission, or when participant feels the need/presents clinical symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Mild-to-moderate Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment optimization (escalation/de-escalation) performed by the investigator based on participant self-monitoring of FC values and/or clinical symptoms (patient-reported outcome-2 [PRO-2] scoring).&#xD;
The FC Test and/or PRO-2 scoring will be done by the participant at home every month during active disease, every 3 months in remission, or when a participant feels the need/presents clinical symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment optimization (escalation/de-escalation) performed by the investigator based on clinical symptoms (PRO-2 scoring) only.&#xD;
The PRO-2 scoring will be assessed during clinic visits every 3-months during active disease, every 6 months during remission, or when a participant feels the need; as per recommended standard practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Faecal Calprotectin Home Test</intervention_name>
    <description>A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.&#xD;
This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator.</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PRO-2 Scoring</intervention_name>
    <description>Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_label>Reference arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Participants (≥ 18 years old)&#xD;
&#xD;
          -  Participants with active mild-to-moderate UC (with RB and bowel inflammation confirmed&#xD;
             by endoscopy)&#xD;
&#xD;
          -  Participants with treatment with 5-aminosalicylic acid (5-ASA) ≤ 2.4 g/day or with no&#xD;
             treatment regimen at Baseline&#xD;
&#xD;
          -  Participants who agree to use FC home test (to dose FC in faeces as a marker of&#xD;
             inflammation)&#xD;
&#xD;
          -  Participants with internet access and smartphone with camera&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants currently enrolled in another interventional study&#xD;
&#xD;
          -  Participants not willing to undergo an endoscopy at the end of study&#xD;
&#xD;
          -  Participants with contraindications to treatment with 5-ASA and/or 2nd generation&#xD;
             corticosteroids&#xD;
&#xD;
          -  Participants not willing to perform FC self-testing in faeces at home&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 833-548-1402 (US/Canada)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 862-286-5200 (outside US)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vojenska nemocnice Brno p.o.</name>
      <address>
        <city>Brno</city>
        <zip>63600</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s.r.o.</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50012</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>EGK s.r.o. - Sanatorium sv. Anny</name>
      <address>
        <city>Praha</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ISCARE IVF a.s.</name>
      <address>
        <city>Praha</city>
        <zip>17000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mediendo s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>18600</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZ a.s. - Masaryk Hospital</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <zip>5223GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis &amp; Vlietland</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osrodek Sadan Klinicznych CLINSANTE</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne LukaMed</name>
      <address>
        <city>Chojnice</city>
        <zip>89-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karkonoskie Centrum Bada Klinicznych - Lexmedica SP Z O O</name>
      <address>
        <city>Jelenia Góra</city>
        <zip>58-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korczowski Bartosz, Gabinet Lekarski</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H-T. Centrum Medyczne sp. z o.o.</name>
      <address>
        <city>Tychy</city>
        <zip>43-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyczno Lecznicze Barska</name>
      <address>
        <city>Wloclawek</city>
        <zip>87-806</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Gastroenterologii w Wodzislawiu Slaskim</name>
      <address>
        <city>Wodzislaw Slaski</city>
        <zip>44-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melita Medical</name>
      <address>
        <city>Wrocław</city>
        <zip>50-529</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SANTA FAMILIA Centrum Badan Profilaktyki i Leczenia</name>
      <address>
        <city>Łódź</city>
        <zip>90302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Management strategies</keyword>
  <keyword>Pragmatic trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

